The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection.
作者信息
Schafer Jason J, Ravi Saranyu, Rowland Evelyn V, Shenoda Germin, Leon Nicholas
出版信息
P T. 2011 Jun;36(6):346-64.
Abstract
摘要
相似文献
1
The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection.
P T. 2011 Jun;36(6):346-64.
2
HIV-1 Antiretroviral Resistance in Cuba, 2009-2014.
MEDICC Rev. 2018 Jul;20(3):15-21. doi: 10.37757/MR2018.V20.N3.5.
3
Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
Int J Biochem Cell Biol. 2004 Sep;36(9):1735-51. doi: 10.1016/j.biocel.2004.02.026.
4
A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
Lancet. 2006 Dec 16;368(9553):2125-35. doi: 10.1016/S0140-6736(06)69861-9.
5
Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
Clin Pharmacokinet. 1999 Apr;36(4):289-304. doi: 10.2165/00003088-199936040-00004.
6
HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
AIDS Rev. 2009 Jul-Sep;11(3):165-73.
7
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Cochrane Database Syst Rev. 2016 Dec 10;12(12):CD004246. doi: 10.1002/14651858.CD004246.pub4.
8
Interactions between non-nucleoside reverse transcriptase inhibitor and nucleoside reverse transcriptase inhibitor mutations: phenotypes and mechanisms.
Curr Opin HIV AIDS. 2007 Mar;2(2):88-93. doi: 10.1097/COH.0b013e328055505c.
9
Triple nucleoside analogue antiretroviral therapy: expanding the treatment approaches for management of HIV infection.
Expert Opin Investig Drugs. 1999 Aug;8(8):1147-55. doi: 10.1517/13543784.8.8.1147.
10
Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
Mini Rev Med Chem. 2010 Jan;10(1):62-72. doi: 10.2174/138955710791112578.
本文引用的文献
1
Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women.
HIV Med. 2011 Apr;12(4):257-8. doi: 10.1111/j.1468-1293.2010.00874.x.
2
Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.
Clin Pharmacokinet. 2011 Jan;50(1):25-39. doi: 10.2165/11534740-000000000-00000.
3
Antiretroviral treatment for children with peripartum nevirapine exposure.
N Engl J Med. 2010 Oct 14;363(16):1510-20. doi: 10.1056/NEJMoa1000931.
4
Antiretroviral therapies in women after single-dose nevirapine exposure.
N Engl J Med. 2010 Oct 14;363(16):1499-509. doi: 10.1056/NEJMoa0906626.
5
The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy.
Ther Drug Monit. 2010 Oct;32(5):579-85. doi: 10.1097/FTD.0b013e3181f0634c.
6
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177.
J Acquir Immune Defic Syndr. 2010 Aug;54(4):e7-9. doi: 10.1097/QAI.0b013e3181e2d5e5.
7
Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA.
HIV Med. 2011 Feb;12(2):97-108. doi: 10.1111/j.1468-1293.2010.00856.x.
8
Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Clin Ther. 2010 Feb;32(2):328-37. doi: 10.1016/j.clinthera.2010.02.013.
9
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
J Infect Dis. 2010 Mar;201(5):672-80. doi: 10.1086/650542.
10
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.
J Antimicrob Chemother. 2010 Feb;65(2):316-9. doi: 10.1093/jac/dkp451. Epub 2009 Dec 23.
Zotero 插件